It has been demonstrated by Cheng Liu et al. that sorafenib plus GdCl3 significantly inhibited angiogenesis, proinflammatory cytokines, and the interactions among HSCs, SECs and KCs as well as ameliorated the increases in ALT, AST and TBIL in dimethylnitrosamine (DMN)-induced hepatic fibrosis rats compared to either single agent, suggesting TKIs combination regimen is a more potent therapy in hepatic fibrosis [87]. The gene discussed is GPT; the disease is Hepatic fibrosis.